Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950564 | 0.84 | NAMPT (0.46) | NAMPTJAK2JAK3PTK2GPR119 | |
| SCHEMBL5821272 | 0.84 | HRH3 (0.40) | TLR9TLR8TLR7VCPEGFR | |
| SCHEMBL5822415 | 0.83 | PDE4B (0.53) | NAMPTJAK2JAK3PTK2TLR9 | |
| SCHEMBL4675927 | 0.77 | GPR119 (0.50) | NAMPTGPR119TGFBR1STS | |
| SCHEMBL5821305 | 0.76 | PDE4B (0.53) | JAK2JAK3PTK2TLR8TLR7 | |
| SCHEMBL15642665 | 0.75 | P2RY14 (0.49) | NAMPTGPR119TLR9TLR8TLR7 | |
| SCHEMBL5805879 | 0.74 | NAMPT (0.46) | NAMPTJAK2JAK3PTK2GPR119 | |
| SCHEMBL16835137 | 0.74 | ALOX12 (0.59) | NAMPTJAK2JAK3PTK2GPR119 | |
| SCHEMBL28847619 | 0.73 | GPR119 (0.48) | NAMPTJAK2GPR119TLR9TLR8 | |
| SCHEMBL18379198 | 0.73 | GPR119 (0.62) | NAMPTGPR119DDB1CRBNTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | NAMPT 404/4885JAK2 1040/4885JAK3 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.